BOAF1 - Overcoming the Challenges of Cancer Drug Resistance: Applying Evolutionary Principles from Bench to Bedside

Monday, November 11, 2024

11:00 AM – 12:30 PM MST

Location: Kaibab & Lantana

Chair(s)

Yan Ji, PhD

Director
Novartis, United States

Co-Chair(s)

Molly Zhao, PhD

Director
Gilead Sciences, New Jersey, United States

Speaker(s)

Jeffrey West, PhD

Assistant Member
Integrated Mathematical Oncology
H. Lee Moffitt Cancer Center & Research Institute
Yanguang Cao, PhD (he/him/his)

Associate Professor
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States
Birgit Schoeberl, PhD

Global Head of Translational Modeling & Simulation and Data Science
Novartis
Cambridge, Massachusetts, United States

Disclosure(s):

Yan Ji, PhD: No financial relationships to disclose

Molly Zhao, PhD: Gilead Sciences: Employment (Ongoing), Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing); Keymed Biosciences: Employment (Ongoing), Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing)

Jeffrey West, PhD: No financial relationships to disclose

Yanguang Cao, PhD: No financial relationships to disclose

Birgit Schoeberl, PhD: Novartis: Employment (Ongoing)

Presentations:

11:00 AM – 11:30 AM MST

Designing evolution-based treatment strategies based on the principles of convexity and concavity
Speaker: Jeffrey West, PhD – H. Lee Moffitt Cancer Center & Research Institute
11:30 AM – 12:00 PM MST

Evolutionary and spatiotemporal response dynamics in metastatic colorectal cancers
Speaker: Yanguang Cao, PhD (he/him/his) – University of North Carolina at Chapel Hill
12:00 PM – 12:30 PM MST

Drug combinations paired with strategic scheduling: leveraging quantitative systems pharmacology to overcome drug resistance
Speaker: Birgit Schoeberl, PhD – Novartis